Brain Classic NM Flashcards
AD FDG
Bilateral posterior parieto - temporal cortex
Posterior cingulate gyrus
Frontal lobe (advanced)
FDG 100% vs SPECT 90% sensitivity in discriminating AD patients
DLB FDG
Medial occipital cortex
FTD FDG
Fronto - temporal regions
Amyloid plaques in cortical gray matter
AD 100%
DLB 50-70%
Normal elderly
Amyloid imaging tracers
DD AD vs FTD
Identify MCI who will convert to AD
Early diagnosis of AD
C11PiB - - more sensitive than FDG
NeuraCeq
Amyvid
Vizamyl
NeuraCeq
F-florbetaben
8 mCi 120 min
Amyvid
F-florbetapir
10 mCi 45 min
Binding similar to PiB
Vizamyl
F-flutemetamol
5 mCi 90 min
Clinically diagnosed AD vs MCI in healthy elderly
Amyloid imaging AD
Frontal, parietal, temporal cortex
No dd AD vs DLB - - DatScan - - bilateral striatum - - AD
Amyloid imaging DLB
AD-like atrophy in parahippocampal area,
Lateral temporal, parietal cortex
Reduced Dat uptake
Amyloid imaging FTD
No amyloid - - no uptake
Brain SPECT tracers AD
Tc-ECD
TC-HMPAO
Both are small, lipophilic, neutral molecules - - cross intact BBB
Fast washout from extra-cerebral tissue, high contrast grey/white
Reduced perfusion in temporoparietal and frontal areas
DatScan preparation and protocol
I123-FP-CIT - cocaine analog
Thyroid block - lugol 100 mg or potassium perchlorate 400 mg 30-60 min before tracer injection
FOV with radius <16 cm, total time 30-45 min, min 1.5 ml counts
Scan after 3-6h when striatal/occipital binding ratio is stable
Sertraline in DatScan
Increase uptake but not interfere with visual presentation
Reduce binding to presinaptic dopamine transporter Dat
Cocaine, amphetamine, methylphenidate, ephedrine, phentermine
Anti Parkinson drug do not interfere with binding!!
FDOPA PD
Presynaptic dopamine transporter imaging
5 mCi 60-90 min
Striatal activity due to activity of AADC (aromatic amino acid decarboxylase)
Transport into storage vesicle by VMAT2
Reduced striatal uptake - - PD
Biomarker for in vivo striatal dopamine level
Postsynaptic D2 dopaminergic imaging tracer PD
Dd PD (presynaptic) and Parkinson plus (postsynaptic)
C11-raclopride
I123 - iodobenzamide = IBZM
Increased binding to putamen contralateral to more affected body side
Degeneration of presynaptic (PD untreated) - - upregulation of postsynaptic
I123 MIBG PD
Myocardial uptake - - no PD
Degeneration of adrenergic post-ganglion pathways - - no cardiac uptake - - PD
Presence of LB - hallmark of PD
Marker of DLB
PD symptoms
Bradykinesia
Rest tremor
Rigidity
Gait abnormality
Vascular cause of PD
Poor response to L-dopa
DatScan normal
Comma shaped uptake with symmetric borders
Rule out PD and DLB - - AD
DatScan abnormal
Reduced uptake in striatum, esp putamen, assymetrical (contralateral)
PD or DLB vs AD (normal)
One side caudate + putamen = infarct
DatScan indication
Dd DLB vs AD (normal)
DD PD vs essential tremor (normal)
Early diagnosis of PD
DD PD vs drug-induced parkinsonism or psychogenic parkinsonism
Not for disease progression and response to treatment
AD
FDG
FTD
FDG
AD
Amyloid imaging
PD
DatScan
PD
FDOPA
MSA FDG
MSA = multiple system atrophy
Putamen and cerebellum
PSP FDG
PSP = progressive supranuclear palsy
Upper brain stem, medial prefrontal cortex, medial thalamus, caudate, anterior cingulate, superior frontal cortex
CBD FDG
CBD = corticobasal degeneration
Assymetrical cortical and subcortical regions
DLB PD FDG
Visual hallucinations
Bilateral occipital cortex
PSP and MSA postsynaptic dopaminergic imaging
Reduced striatal binding due to reduced D2 receptor binding
Also in patients taking dopaminergic drugs
MSA MIBG
MSA - - orthostatic hypotension ass with parkinsonism
Cardiac uptake of MIBG
DD MSA vs orthostatic hypotension in PD treated by L-DOPA
Also no Lewy Body in MSA vs PD and DLB
Brain perfusion SPECT
Multidetector gamma camera with LEHR or LEUHR or fan-beam collimator - - highest spatial resolution
Stop benzodiazepine
Stop dilantin
No coffee, smoke, alco
Sedation after tracer
10 min before and 5 min after injection silent and low light
SPECT 20 min after tracer
30 min acquisition - - FBP or iterative algorithm with low pass filter (Butterworth 0.5 cycle/cm, order 6-8)
Benzodiazepine cause
Globul perfusion reduction
Dilantin cause
Cerebellar hypoperfusion
TC-HMPAO
15-30 mCi
Stable for 30 min
Cross intact BBB by simple diffusion
Labeled autologous leukocytes
More adequate to identify areas with hyperperfusion (epilepsy), but in vitro not stable
If subacute stroke - - better cerebral perfusion
Tc-ECD
15-30 mCi
Stable for 6-8 h
Stereomer 1.1-ECD
More rapid clearance from bloodstream - - better target-to-background ratio
Cross intact BBB - - passive diffusion
If subacute stroke - - better metabolic activity
Tc-DTPA
15-20 mCi
Brain death (not cross BBB)
Short T1/2 - - for children
Brain death
Coma+absence of brain stem reflexes +apnea - - at least two of them - - no need for test
Dynamic - - frame/sec for 1 min - - late planar 20-30 min - - SPECT
“hot nose” sign = rerouted blood flow
Epilepsy
Drug resistant - - surgery
First day - interictal SPECT (between seizures)
Second day - ictal SPECT under video-EEG (within 45 sec of seizure onset) - - hyperperfusion
Diamox
= acetazolamide
Increase CO2 - - vasodilation - - increase blood flow 3-4 times
1g IV - - 20 min - - cerebral vascular reserve - - flow decreases if vascular disease and impaired reserve
Indication: carotid occlusion - - define risk of stroke and select patients for revascularization
Reduced vascular reserve
Elipelsy
Brain death
Cysternography
IN111-DTPA, long T1/2
Intrathecal injection into subarachnoid space 0.5-1 mCi 1 ml (remove 1 ml CSF)
Early image over lumbar region 1-2H - - check injection
Planar image of skull 6, 24, 48 h
Normal cysternography
Basal cisterns after 4h
Sylvian and interhemispheric cisterns
Subarachnoid space at 6h
Washout from basal cisterns at 24-48h
Hydrocephalus
Lateral ventricles at 6h - - persists 24-48h
Reflux into ventricles
Evaluate shunt patency
Tc-DTPA into reservoir of catheter of device under skin - - transit into peritoneal cavity within 30-60 min
No activity in peritoneal cavity - - distal obstruction
Fails to reach ventricles - - proximal obstruction
CSF leakage
Rhinorrhea, otorrhea
Fistula - - place pledget in nostril after Intrathecal administration
Cross compromised BBB
Tc-DTPA
Tc-pert
Brain death tracers
Tc-DTPA
Tc-HMPAO
Tc–ECD